ENDORSEMENTS

Home » Endorsements

At SVMPharma we have always had a single minded goal to work with clients to build successful relationships and generate the outcomes that matter. We work diligently as an extended part of your team, to provide the training, support and product to enhance your service offerings. However, do not just take our word for this

collons

I came across SVMPharma after reading a report about some work they had done in oncology – very impressive work that had affected a NICE decision. We met with SVMPharma and we are now engaged on a couple of projects with SVMPharma – working very closely. They facilitate the paperwork to allow data collection, become part of the cross-functional team driving results and bring a wealth of experience to the table too. SVMPharma has been a pleasure to work with and I would strongly recommend contacting them to get their input first-hand on real-world data.

European Managing Director

Delivering clinical trials is our passion and area of expertise. Each clinical trial has its own objectives and requirements. Phase 1-3 clinical trials have set objectives and clear outcomes, our focus is on the need to implement, execute and deliver the trial. Whereas real-world evidence studies start with a business need and objective that are not met with data from current clinical trials. SVMPharma translate the business needs and objectives into a real-world evidence study starting with clients’ concepts, healthcare professional’s insights through to study execution and final study outcomes leading to:

Icon Set
Icon Set-2-white

New clinical
data

Icon Set2
Icon Set-2-white2

Peer reviewed publications

Icon Set3
Icon Set-2-white3

Congress presentations / abstracts

Icon Set4
Icon Set-2-white4

Value propositions

Icon Set5
Icon Set-2-white5

Marketing
messages

Icon Set6
Icon Set-2-white6

Successful reimbursement submissions

Peer reviewed publications

2022 February

Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

READ MORE

2022 February

Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors

READ MORE

2022 February

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

READ MORE

2022 February

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient– Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

READ MORE

2022 February

Aztreonam Lysine (Cayston)

READ MORE

CLIENT AND PARTNER FEEDBACK

collons

I came across SVMPharma after reading a report about some work they had done in oncology – very impressive work that had affected a NICE decision. We met with SVMPharma and we are now engaged on a couple of projects with SVMPharma – working very closely. They facilitate the paperwork to allow data collection, become part of the cross-functional team driving results and bring a wealth of experience to the table too. SVMPharma has been a pleasure to work with and I would strongly recommend contacting them to get their input first-hand on real-world data.

European Managing Director
collons

…the experience so far has been very positive with good communication, open discussions and things being done to a high standard. [The client] was a bit sceptical to work with a small company at the start, but compared to global vendors he’s worked with in the past, SVM has ‘knocked them out of the park.

Medical Director
collons

[The study] will be an important benchmark for the future.

Consultant Medical Oncologist